


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app40.us.archive.org';v.server_ms=298;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>EFNS/MDS-ES recommendations for the diagnosis of Parkinson&#39;s disease. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180712203442im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180712203442im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180712203442im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180712203442im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180712203442/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180712203442im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180712203442cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712203442js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180712203442if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712203442/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180712203442if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712203442/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180712203442/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180712203442/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180712203442/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180712203442im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180712203442im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180712203442im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180712203442/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180712203442/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180712203442/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180712203442/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180712203442/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180712203442/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180712203442/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180712203442/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180712203442/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180712203442/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180712203442/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180712203442/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180712203442/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180712203442/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180712203442/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180712203442/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180712203442/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180712203442/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180712203442/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180712203442/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712203442/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:009637</li>
            <li>2013 Jan
            </li>            
                                </ul>
        <div>
                <h1>EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180712203442/https://www.guideline.gov/search?f_Guideline_Developer_String=European%20Academy%20of%20Neurology&amp;fLockTerm=European%2BAcademy%2Bof%2BNeurology">European Academy of Neurology</a></li>
                        <li>   
                                <a id="1856" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
        <li><a href="/web/20180712203442/https://www.guideline.gov/search?f_Guideline_Developer_String=Movement%20Disorders%20Society--European%20Section&amp;fLockTerm=Movement%2BDisorders%2BSociety--European%2BSection">Movement Disorders Society--European Section</a></li>
                        <li>   
                                <a id="2460" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):16-34. [245 references] <a href="https://web.archive.org/web/20180712203442/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23279440" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712203442im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table>                    <p><a href="/web/20180712203442/https://www.guideline.gov/Home/Disclaimer?id=43845&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fonlinelibrary.wiley.com%252fdoi%252f10.1111%252fene.12022%252fepdf">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712203442im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                            <h4>UMLS Concepts <a href="/web/20180712203442/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180712203442/https://www.guideline.gov/search?f_ICD9CM_CUI=C0030567&amp;fLockTerm=Paralysis+agitans">Paralysis agitans</a>
 (332.0), <a href="/web/20180712203442/https://www.guideline.gov/search?f_ICD9CM_CUI=C0751772&amp;fLockTerm=REM+sleep+behavior+disorder">REM sleep behavior disorder</a>
 (327.42), <a href="/web/20180712203442/https://www.guideline.gov/search?f_ICD9CM_CUI=C0033975&amp;fLockTerm=Unspecified+psychosis">Unspecified psychosis</a>
 (298.9)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0011570&amp;fLockTerm=Depression">Depression</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0679560&amp;fLockTerm=Genetic+Testing">Genetic Testing</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0024485&amp;fLockTerm=Magnetic+Resonance+Imaging">Magnetic Resonance Imaging</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0025084&amp;fLockTerm=Medical+History+Taking">Medical History Taking</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0679575&amp;fLockTerm=Neuroimaging">Neuroimaging</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0027902&amp;fLockTerm=Neuropsychological+Tests">Neuropsychological Tests</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0030567&amp;fLockTerm=Parkinson+Disease">Parkinson Disease</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0033975&amp;fLockTerm=Psychotic+Disorders">Psychotic Disorders</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0034606&amp;fLockTerm=Radionuclide+Imaging">Radionuclide Imaging</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0751772&amp;fLockTerm=REM+Sleep+Behavior+Disorder">REM Sleep Behavior Disorder</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0040399&amp;fLockTerm=Tomography%2c+Emission-Computed%2c+Single-Photon">Tomography, Emission-Computed, Single-Photon</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0041618&amp;fLockTerm=Ultrasonography">Ultrasonography</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MSH_CUI=C0206077&amp;fLockTerm=Ultrasonography%2c+Doppler%2c+Transcranial">Ultrasonography, Doppler, Transcranial</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0870300&amp;fLockTerm=Assessment%3a+Cognition">Assessment: Cognition</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0679560&amp;fLockTerm=Genetic+screening+method">Genetic screening method</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0024485&amp;fLockTerm=Magnetic+Resonance+Imaging">Magnetic Resonance Imaging</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0011570&amp;fLockTerm=Mental+Depression">Mental Depression</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0030567&amp;fLockTerm=Parkinson+Disease">Parkinson Disease</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0033975&amp;fLockTerm=Psychotic+Disorders">Psychotic Disorders</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0034606&amp;fLockTerm=Radionuclide+Imaging">Radionuclide Imaging</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0040399&amp;fLockTerm=Tomography%2c+Emission-Computed%2c+Single-Photon">Tomography, Emission-Computed, Single-Photon</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0041618&amp;fLockTerm=Ultrasonography">Ultrasonography</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_MTH_CUI=C0206077&amp;fLockTerm=Ultrasonography%2c+Doppler%2c+Transcranial">Ultrasonography, Doppler, Transcranial</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180712203442/https://www.guideline.gov/search?f_PDQ_CUI=C0870300&amp;fLockTerm=cognitive+assessment">cognitive assessment</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_PDQ_CUI=C0024485&amp;fLockTerm=magnetic+resonance+imaging">magnetic resonance imaging</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_PDQ_CUI=C0034606&amp;fLockTerm=radionuclide+imaging">radionuclide imaging</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_PDQ_CUI=C0040399&amp;fLockTerm=tomography%2c+emission+computed%2c+single+photon">tomography, emission computed, single photon</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_PDQ_CUI=C0041618&amp;fLockTerm=ultrasonography">ultrasonography</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0679560&amp;fLockTerm=Genetic+test">Genetic test</a>
 (405824009), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024485&amp;fLockTerm=Magnetic+resonance+imaging">Magnetic resonance imaging</a>
 (113091000), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024485&amp;fLockTerm=Magnetic+resonance+imaging">Magnetic resonance imaging</a>
 (312250003), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0336660&amp;fLockTerm=Magnetic+resonance+imaging+unit">Magnetic resonance imaging unit</a>
 (90003000), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0027902&amp;fLockTerm=Neuropsychological+testing">Neuropsychological testing</a>
 (307808008), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0034606&amp;fLockTerm=Nuclear+medicine+imaging+procedure">Nuclear medicine imaging procedure</a>
 (373205008), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0437485&amp;fLockTerm=O%2fE+-+smell+tested">O/E - smell tested</a>
 (164083001), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0030567&amp;fLockTerm=Parkinson%27s+disease">Parkinson&#39;s disease</a>
 (49049000), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033975&amp;fLockTerm=Psychotic+disorder">Psychotic disorder</a>
 (69322001), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0751772&amp;fLockTerm=REM+sleep+behavior+disorder">REM sleep behavior disorder</a>
 (415238003), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0588008&amp;fLockTerm=Severe+depression">Severe depression</a>
 (310497006), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C2585833&amp;fLockTerm=Single+photon+emission+computed+tomography+of+heart+using+iodine+123+meta-iodobenzylguanidine">Single photon emission computed tomography of heart using iodine 123 meta-iodobenzylguanidine</a>
 (440043007), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040399&amp;fLockTerm=Single+photon+emission+computerized+tomography">Single photon emission computerized tomography</a>
 (105371005), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040399&amp;fLockTerm=Single+photon+emission+computerized+tomography">Single photon emission computerized tomography</a>
 (260222006), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1997397&amp;fLockTerm=Single+photon+emission+computerized+tomography+for+dopamine+transport">Single photon emission computerized tomography for dopamine transport</a>
 (429781007), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0206077&amp;fLockTerm=Transcranial+doppler+ultrasonography">Transcranial doppler ultrasonography</a>
 (431648005), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041618&amp;fLockTerm=Ultrasonography">Ultrasonography</a>
 (16310003), <a href="/web/20180712203442/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041618&amp;fLockTerm=Ultrasonography">Ultrasonography</a>
 (278292003)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SPN</h5>
                    <div class="field-content">
<a href="/web/20180712203442/https://www.guideline.gov/search?f_SPN_CUI=C0302622&amp;fLockTerm=SYSTEM%2c+IMAGING%2c+PULSED+DOPPLER%2c+ULTRASONIC">SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC</a>
, <a href="/web/20180712203442/https://www.guideline.gov/search?f_SPN_CUI=C0336660&amp;fLockTerm=SYSTEM%2c+NUCLEAR+MAGNETIC+RESONANCE+IMAGING">SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">UMD</h5>
                    <div class="field-content">
<a href="/web/20180712203442/https://www.guideline.gov/search?f_UMD_CUI=C1608350&amp;fLockTerm=Analyzers%2c+Laboratory%2c+Molecular+Assay%2c+Genetic+Testing">Analyzers, Laboratory, Molecular Assay, Genetic Testing</a>
 (20-803), <a href="/web/20180712203442/https://www.guideline.gov/search?f_UMD_CUI=C0810606&amp;fLockTerm=Scanning+Systems%2c+Gamma+Camera%2c+Single+Photon+Emission+Tomography">Scanning Systems, Gamma Camera, Single Photon Emission Tomography</a>
 (18-444), <a href="/web/20180712203442/https://www.guideline.gov/search?f_UMD_CUI=C0336660&amp;fLockTerm=Scanning+Systems%2c+Magnetic+Resonance+Imaging">Scanning Systems, Magnetic Resonance Imaging</a>
 (16-260), <a href="/web/20180712203442/https://www.guideline.gov/search?f_UMD_CUI=C0302622&amp;fLockTerm=Scanning+Systems%2c+Ultrasonic">Scanning Systems, Ultrasonic</a>
 (14-278)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/downloadcontent/ngc-9637?contentType=pdf" class="pdf">.PDF 99.0 kb</a></li>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/downloadcontent/ngc-9637?contentType=word" class="word">Word Document 290.4 kb</a></li>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/downloadcontent/ngc-9637?contentType=xml" class="xml">.XML 39.6 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180712203442/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712203442/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712203442/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180712203442/mailto:/?Subject=AHRQ: EFNS/MDS-ES recommendations for the diagnosis of Parkinson&amp;#39;s disease.&amp;body=https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Jan 01. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/citedownload/43845?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/citedownload/43845?format=enw">EndNote</a></li>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/citedownload/43845?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/citedownload/43845?format=txt">Medlars</a></li>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/citedownload/43845?format=ris">ProCite</a></li>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/citedownload/43845">RefWorks</a></li>
                            <li><a href="/web/20180712203442/https://www.guideline.gov/summaries/citedownload/43845?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="43845" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>The levels of evidence (Class I&ndash;IV) supporting the recommendations and ratings of recommendations (A&ndash;C) are defined at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Section 1: Clinical Diagnostic Criteria for Parkinson's Disease (PD)</span></strong></p>
<p>Only the Queen Square Brain Bank (QSBB) clinical diagnostic criteria have been validated by Hughes et al. (2002) and are therefore recommended as <em>probably effective</em> (<strong>Level B</strong>) for clinical practice.</p>
<p><strong><span style="text-decoration: underline;">Section 2: Genetic Testing</span></strong></p>
<p>Available evidence provides a <strong>Level B</strong> recommendation for the use of genetic testing in the diagnosis of PD. Genetic testing for specific mutations is recommended on an individual basis, and specific features, particularly family history and age of onset, must be taken into account:</p>
<ol style="list-style-type: upper-roman;">
    <li>Testing for <em>alpha-synuclein (SNCA)</em> point mutations and gene multiplications is recommended only in families with multiple affected members in more than one generation suggestive of dominant inheritance, with early- or late-onset PD. </li>
    <li><em>Leucine-rich repeat kinase 2 (LRRK2)</em> genetic testing for counselling purposes, specifically directed at known pathogenic variants is recommended in patients with a clinical picture of typical PD and a positive family history suggestive of dominant inheritance. </li>
    <li>In sporadic patients, genetic testing should be limited to the search for known <em>LRRK2</em> founder mutations in the appropriate populations (i.e., with known high mutation frequencies). </li>
    <li>Genetic testing for glucocerebrosidase (GBA) gene mutations is recommended in patients with typical PD with or without a positive family history, limited to the known founder mutations of established pathogenic role in the appropriate populations. </li>
    <li>Genetic testing of the <em>parkin, PINK1</em> and <em>DJ-1</em> genes for counselling purposes is recommended in patients with typical PD and positive family history compatible with recessive inheritance, particularly when the disease onset is before the age of 50 years. For sporadic cases, <em>parkin, PINK1</em> and <em>DJ-1</em> genetic testing is recommended when onset is very early, particularly before the age of 40. </li>
    <li>Testing of the <em>ATP13A2, PLA2G6</em> and <em>FBXO7</em> genes might be considered in cases with very-early-onset PD, if no mutation in <em>parkin, PINK1</em> and <em>DJ-1</em> gene has been found. </li>
</ol>
<p><strong><span style="text-decoration: underline;">Section 3: Autonomic Function Tests</span></strong></p>
<p><strong>Neurophysiological Assessment of Autonomic Function</strong></p>
<p>Autonomic function tests (AFTs) are principally helpful to detect autonomic impairments in patients with PD. Some dysautonomic features, like orthostatic hypotension (OH) or post-void residual volume, have important therapeutic implications. However, at the moment, there is insufficient evidence to provide a level of recommendation for AFTs in PD.</p>
<p><strong><span style="text-decoration: underline;">Section 4: Olfactory Tests</span></strong></p>
<p>Olfactory testing differentiates PD from:</p>
<ol style="list-style-type: upper-roman;">
    <li>Atypical and secondary parkinsonian disorders (<strong>Level A</strong>) </li>
    <li>Recessive forms of PD (<strong>Level A</strong>) </li>
</ol>
<p>Current evidence suggests that olfactory testing may be considered as a diagnostic screening procedure (<strong>Level A</strong>), but not as an indicator of disease progression (<strong>Level B</strong>) in PD. Olfactory testing is a sensitive screening test for pre-motor PD (<strong>Level A</strong>), but not specific. Thus, olfactory testing can be envisioned in a screening battery for PD. If hyposmia is detected, then other specific tests for PD should follow.</p>
<p><strong><span style="text-decoration: underline;">Section 5: Drug Challenge Tests</span></strong></p>
<p>Drug challenge tests are not recommended for the diagnosis of de novo parkinsonian patients. There is insufficient evidence to support their role in the differential diagnosis between PD and other parkinsonian syndromes.</p>
<p><strong><span style="text-decoration: underline;">Section 6: Neurophysiological Tests</span></strong></p>
<p>No recommendation can be given on neurophysiological tests because of the low evidence level of the available studies.</p>
<p><strong><span style="text-decoration: underline;">Section 7: Neuropsychological Tests</span></strong></p>
<p>An assessment of neuropsychological functioning in a person presenting with parkinsonism suspected of being PD is recommended (<strong>Level A</strong>) and should include:</p>
<ol style="list-style-type: upper-roman;">
    <li>A collateral history from a reliable carer </li>
    <li>A brief assessment of cognition </li>
    <li>Screening for rapid eye movement (REM) sleep behaviour disorder (RBD), psychotic manifestations and severe depression </li>
</ol>
<p><strong><span style="text-decoration: underline;">Section 8: Neuroimaging</span></strong></p>
<p><strong>Transcranial Sonography (TCS)</strong></p>
<p>TCS is recommended (<strong>Level A</strong>) for:</p>
<ol style="list-style-type: upper-roman;">
    <li>Differential diagnosis of PD from atypical parkinsonian syndromes (APS) and secondary parkinsonian syndromes </li>
    <li>Early diagnosis of PD </li>
    <li>Detection of subjects at risk for PD </li>
</ol>
<p>The technique is so far not universally used and requires some expertise. Because specificity of TCS for the development of PD is limited, TCS should be used in conjunction with other screening tests.</p>
<p><strong>Magnetic Resonance Imaging</strong></p>
<p>The Task Force concludes that conventional magnetic resonance imaging (cMRI) at 1.5 T is principally helpful to exclude symptomatic parkinsonism due to other pathologies (<strong>Level B</strong>).</p>
<p>1.5-T cMRI is also useful in the differentiation of PD from APS as follows:</p>
<ol style="list-style-type: upper-roman;">
    <li>Multiple system atrophy (MSA) signs &ndash; putaminal atrophy and rim sign, pontocerebellar atrophy, middle cerebellar peduncle (MCP) hyperintensity and hot cross bun sign (<strong>all Level A</strong>) </li>
    <li>Progressive supranuclear palsy (PSP) signs &ndash; midbrain atrophy and hummingbird sign (<strong>both Level B</strong>), superior cerebellar peduncle (SCP) atrophy (<strong>Level C</strong>) </li>
</ol>
<p>Specificity of these abnormalities to differentiate APS from PD is considered quite high, whereas sensitivity, particularly in early disease stages, seems to be insufficient. A normal routine 1.5-T cMRI does not exclude MSA or PSP, if the clinical presentation is suggestive and supported by the current diagnostic criteria.</p>
<p>Abnormalities on diffusion-weighted imaging (DWI) at 1.5 T including diffusivity changes in:</p>
<ol style="list-style-type: upper-roman;">
    <li>Putamen in patients with APS versus PD in early disease stages (especially MSA-parkinsonian subtype [MSA-P], <strong>Level A</strong>) </li>
    <li>SCP in patients with PSP (<strong>Level B</strong>) have been described as markers, which can point the diagnosis towards MSA or PSP instead of PD </li>
</ol>
<p>Newer quantitative imaging techniques implemented on 3-T systems have shown promising results. However, they require further confirmatory studies.</p>
<p><strong>Single Photon Emission Tomography</strong></p>
<p>Dopamine transporter-single photon emission tomography (DaTscan-SPECT) is registered in Europe and the United States for the differential diagnosis between degenerative parkinsonism and essential tremor (<strong>Level A</strong>). More specifically, DaTscan-SPECT is indicated in the presence of significant diagnostic uncertainty and particularly in patients presenting atypical tremor manifestations. Cardiac [<sup>123</sup>I] meta-iodobenzylguanidine (MIBG)/SPECT imaging may assist in the differential diagnosis of PD versus APS (<strong>Level A</strong>).</p>
<p>All other SPECT imaging studies do not fulfill registration standards and cannot be recommended for routine clinical use.</p>
<p><strong>Positron Emission Tomography (PET)</strong></p>
<p>None of the reviewed PET studies has been performed according to regulatory standards with the exception of the study by Whone et al. (2003). Therefore, the Task Force cannot make any formal recommendation for the routine use of PET studies in the diagnostic work-up of PD.</p>
<p><strong><span style="text-decoration: underline;">Definitions</span></strong>:</p>
<p><strong>Evidence Classification Scheme for a Diagnostic Measure</strong></p>
<p><strong>Class I</strong>: A prospective study in a broad spectrum of persons with the suspected condition, using a 'gold standard' for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.</p>
<p><strong>Class II</strong>: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by 'gold standard') compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.</p>
<p><strong>Class III</strong>: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation.</p>
<p><strong>Class IV</strong>: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls).</p>
<p><strong>Rating of Recommendations for a Diagnostic Measure</strong></p>
<p><strong>Level A rating</strong> (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies.</p>
<p><strong>Level B rating</strong> (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence.</p>
<p><strong>Level C rating</strong> (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies.</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Parkinson's disease</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Diagnosis</p>
                    <p>Screening</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Family Practice</p>
                    <p>Medical Genetics</p>
                    <p>Neurology</p>
                    <p>Radiology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Nurses</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To develop guidelines for the diagnosis of Parkinson's disease to be applied across Europe</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Individuals at risk for Parkinson's disease</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><ol style="list-style-type: decimal;" start="1">
    <li>Clinical diagnostic criteria (Queen Square Brain Bank [QSBB]) </li>
    <li>Genetic testing for the following mutations:
    <ul style="list-style-type: disc;">
        <li><em>Alpha-synuclein (SNCA)</em> </li>
        <li><em>Leucine-rich repeat kinase 2 (LRRK2)</em> </li>
        <li><em>Glucocerebrosidase (GBA)</em> </li>
        <li><em>parkin</em>, <em>PINK1</em>, and <em>DJ-1</em> </li>
        <li><em>ATP13A2</em>, <em>PLA2G6</em>, and <em>FBXO7</em> </li>
    </ul>
    </li>
    <li>Olfactory tests </li>
    <li>Neuropsychological tests
    <ul style="list-style-type: disc;">
        <li>Collateral history </li>
        <li>Brief assessment of cognition </li>
        <li>Screening for rapid eye movement (REM) sleep behavior disorder (RBD), psychotic manifestations, and severe depression </li>
    </ul>
    </li>
    <li>Neuroimaging
    <ul style="list-style-type: disc;">
        <li>Transcranial sonography (TCS) </li>
        <li>Conventional magnetic resonance imaging (cMRI) </li>
        <li>Dopamine transporter-single photon emission tomography (DaTscan-SPECT) </li>
        <li>Cardiac [<sup>123</sup>I] meta-iodobenzylguanidine (MIBG)/SPECT imaging </li>
    </ul>
    </li>
</ol>
<p class="Note"><strong>Note</strong>: The following interventions were considered but not recommended: autonomic function tests, drug challenge tests, neurophysiological tests, SPECT imaging other than DaTscan-SPECT or cardiac [<sup>123</sup>I] meta-iodobenzylguanidine (MIBG)/SPECT, positron emission tomography (PET).</p></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><div class="content_para"><p>Sensitivity and specificity of diagnostic tests</p></div></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p>This European Federation of Neurological Societies/Movement Disorder Society&ndash;European Section (EFNS/MDS&ndash;ES) Task Force report is divided into nine sections addressing key aspects of the diagnostic work-up of patients presenting with parkinsonism.</p>
<p>Groups of experts were allocated to each section and asked to provide an evidence-based recommendation level for the assigned diagnostic tool. To this end, MEDLINE, EMBASE and Cochrane libraries were searched for relevant citations up to June 2011.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Evidence Classification Scheme for a Diagnostic Measure</strong></p>
<p><strong>Class I</strong>: A prospective study in a broad spectrum of persons with the suspected condition, using a 'gold standard' for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.</p>
<p><strong>Class II</strong>: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by 'gold standard') compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.</p>
<p><strong>Class III</strong>: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation.</p>
<p><strong>Class IV</strong>: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls).</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Systematic Review</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p>This European Federation of Neurological Societies/Movement Disorder Society&ndash;European Section (EFNS/MDS&ndash;ES) Task Force report is divided into nine sections addressing key aspects of the diagnostic work-up of patients presenting with parkinsonism.</p>
<p>Groups of experts were allocated to each section and asked to provide an evidence-based recommendation level for the assigned diagnostic tool. Consensus on the guidelines was finally reached within the Task Force.</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Rating of Recommendations for a Diagnostic Measure</strong></p>
<p><strong>Level A rating</strong> (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies.</p>
<p><strong>Level B rating</strong> (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence.</p>
<p><strong>Level C rating</strong> (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies.</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p><strong>Economic Issues</strong></p>
<p>Cost-effectiveness data are scarce in Parkinson's disease (PD). Only <sup>123</sup>I-2beta-carbometoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (<sup>123</sup>I-FP-CIT) single photon emission tomography (SPECT) was assessed in three jurisdictions (Italy, Belgium and Germany). In all three publications, the authors came to the conclusion that <sup>123</sup>I-FP-CIT SPECT has to be regarded as cost-effective investigation for the differential diagnosis of essential tremor from parkinsonian disorders, if used as a confirmatory test in drug-naive patients with a positive clinical examination. There are insufficient cost-effectiveness data for all the other diagnostic modalities reviewed in this statement. This is an area of unmet need deserving future investigations.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>The guidelines were validated according to the European Federation of Neurological Societies (EFNS) criteria (see the "Availability of Companion Documents" field).</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">References Supporting the Recommendations</a></h3>
                    <p><table><tr><td>Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002 Apr;125(Pt 4):861-70. <a href="https://web.archive.org/web/20180712203442/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11912118" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712203442im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003 Jul;54(1):93-101. <a href="https://web.archive.org/web/20180712203442/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12838524" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712203442im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for selected recommendations (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Accurate diagnosis of Parkinson's disease</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><div class="content_para"><p>This guideline provides the view of an expert Task Force appointed by the Scientific Committee of the European Federation of Neurological Societies (EFNS). It represents a peer-reviewed statement of minimum desirable standards for the guidance of practice based on the best available evidence. It is not intended to have legally binding implications in individual cases.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>The European Federation of Neurological Societies has a mailing list and all guideline papers go to national societies, national ministries of health, World Health Organisation, European Union, and a number of other destinations. Corporate support is recruited to buy large numbers of reprints of the guideline papers and permission is given to sponsoring companies to distribute the guideline papers from their commercial channels, provided there is no advertising attached.</p></div></p>
                        <h3><a href="#">Implementation Tools</a></h3>
                    <p>Staff Training/Competency Material</p>
                    <p><div class="general-block">For information about availability, see the <i>Availability of Companion Documents</i> and <i>Patient Resources</i> fields below.</div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):16-34. [245 references] <a href="https://web.archive.org/web/20180712203442/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23279440" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712203442im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2013 Jan</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>European Academy of Neurology - Medical Specialty Society</p>
                    <p>Movement Disorders Society--European Section - Professional Association</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>European Federation of Neurological Societies</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>European Federation of Neurological Societies/Movement Disorder Society&ndash;European Section Task Force on Diagnosis of Parkinson's Disease</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Task Force Members</em>: A. Berardelli, Dipartimento di Neurologia e Psichiatria and IRCCS NEUROMED Institute, Sapienza, Universit&agrave; di Roma, Rome, Italy; G.K. Wenning, Department of Neurology, Innsbruck Medical University, Innsbruck, Austria; A. Antonini, Parkinson's disease and Movement Disorders Unit IRCCS, San Camillo, Venice, Milan, Italy; D. Berg, Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of T&uuml;bingen and DZNE, T&uuml;bingen, Germany; B.R. Bloem, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Radboud University Nijmegen Medical Center, Nijmegen; V. Bonifati, Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands; D. Brooks, Department of Clinical Neuroscience, Imperial College London, Hammersmith Hospital, London, UK; D.J. Burn, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK; C. Colosimo, Dipartimento di Neurologia e Psichiatria, Sapienza, Universit&agrave; di Roma, Rome, Italy; A. Fanciulli, Department of Neurology, Innsbruck Medical University, Innsbruck, Austria; J. Ferreira, Centro De Estudos Egas Moniz, Faculdade De Medicina De Lisboa, Lisbon, Portugal; T. Gasser, Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of T&uuml;bingen and DZNE, T&uuml;bingen, Germany; F. Grandas, Movement Disorders Research Unit, Hospital Universitario Gregorio Mara&ntilde;&oacute;n, Madrid, Spain; P. Kanovsky, Department of Neurology, Palacky University, Olomouc, Czech Republic; V. Kostic, Institute of Neurology CCS, School of Medicine, University of Belgrade, Belgrade, Serbia; J. Kulisevsky, Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Universitat Autonoma de Barcelona and Ciberned, Barcelona, Spain; W. Oertel, Department of Neurology, Centre of Nervous Diseases, Philipps-University of Marburg, Marburg, Germany; W. Poewe, Department of Neurology, Innsbruck Medical University, Innsbruck, Austria; J.-P. Reese, Institut f&uuml;r Medizinische Soziologie, Deutschland, Germany; M. Relja, Department of Neurology, Movement Disorders Centre, School of Medicine and University Hospital Centre, University of Zagreb, Zagreb, Croatia; E. Ruzicka, 1st Faculty of Medicine and General University Hospital in Prague, Charles University in Prague, Praha, Czech Republic; A. Schrag, Institute of Neurology, University College London, London, UK; K. Seppi, Department of Neurology, Innsbruck Medical University, Innsbruck, Austria; P. Taba, Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia; M. Vidailhet, P&ocirc;le des Maladies du Syst&egrave;me Nerveux et CRICM UPMC/INSERM UMR_S975 CNRS UMR7225, F&eacute;d&eacute;ration de Neurologie, H&ocirc;pital de la Salp&ecirc;tri&egrave;re, Paris, France</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Available to registered users from the <a href="/web/20180712203442/https://www.guideline.gov/Home/Disclaimer?id=43845&amp;contentType=summary&amp;redirect=http%3a%2f%2fonlinelibrary.wiley.com%2fdoi%2f10.1111%2fene.12022%2fepdf" title="European Journal of Neurology Web site">European Journal of Neurology Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712203442im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K, Waldemar G; Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces &ndash; revised recommendations 2004. Eur J Neurol. 2004 Sep;11(9):577-81. Available from the <a href="/web/20180712203442/https://www.guideline.gov/Home/Disclaimer?id=43845&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.efns.org%2ffileadmin%2fuser_upload%2fguidline_papers%2fEFNS_guideline_2004_neurological_management_guidelines.pdf" title="European Federation of Neurological Societies Web site">European Federation of Neurological Societies Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712203442im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Continuing Medical Education questions are available to registered users from the <a href="/web/20180712203442/https://www.guideline.gov/Home/Disclaimer?id=43845&amp;contentType=summary&amp;redirect=http%3a%2f%2fonlinelibrary.wiley.com%2fjournal%2f10.1111%2f(ISSN)1468-1331%2fhomepage%2fcme_articles.htm" title="European Journal of Neurology Web site">European Journal of Neurology Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712203442im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on May 16, 2013.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the Wiley Online Library copyright restrictions.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180712203442/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180712203442/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180712203442/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712203442/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712203442/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712203442/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712203442/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712203442/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180712203442/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180712203442/https://www.guideline.gov/disclaimer?id=43845&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180712203442im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180712203442im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180712203442/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180712203442/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180712203442/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180712203442/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180712203442/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180712203442/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180712203442/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180712203442/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180712203442/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180712203442/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180712203442/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180712203442/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180712203442/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180712203442im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180712203442im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180712203442/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180712203442im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180712203442im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180712203442/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180712203442/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180712203442js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180712203442js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 20:34:42 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 17:20:57 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 110.66 (3)
  esindex: 0.011
  captures_list: 131.181
  CDXLines.iter: 15.214 (3)
  PetaboxLoader3.datanode: 38.552 (4)
  exclusion.robots: 0.293
  exclusion.robots.policy: 0.273
  RedisCDXSource: 1.682
  PetaboxLoader3.resolve: 145.889 (2)
  load_resource: 128.243
-->